A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation

Journal of Clinical Psychopharmacology

Volumn 16, Issue 4, 1996, Pages 307-314

  Baumann, Pierre ^a   Nil, R ^b   Souche, Alain ^a   Montaldi, Stefano ^a   Baettig, Dominique ^a   Lambert, Susanne ^a   Uehlinger, Claude ^c   Kasas, Anton ^d   Amey, Marlyse ^a   Jonzier Perey, Michèle ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b H LUNDBECK A S   (Denmark)

^c Hôpital Psychiatrique Cantonal   (Switzerland)

^d Clinique Psychiatrique Cantonale   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYTOCHROME P450; DEXTROMETHORPHAN; LITHIUM; MEPHENYTOIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIDEPRESSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CITALOPRAM; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; DEXTROMETHORPHAN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; MEPHENYTOIN; MIDDLE AGED; MIXED FUNCTION OXYGENASES; SEROTONIN UPTAKE INHIBITORS;

EID: 9344237128     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199608000-00006     Document Type: Article

References (45)

1. Burrows GD, Norman TR, Judd FK. Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol 1994;9[suppl 2]:5-10.
2. Möller H-J. Non-response to antidepressants: risk factors and therapeutic possibilities. Int Clin Psychopharmacol 1994;9 [suppl 2]:17-23.
3. de Montigny C, Grunberg F, Mayer A, Deschenes J-P. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981;138:252-6.
4. Schöpf J. Treatment of depressions resistant to tricyclic antidepressants, related drugs or MAO-inhibitors by lithium addition: review of the literature. Pharmacopsychiatry 1989;22:174-82.
5. Austin MPV, Souza FGM, Goodwin GM. Lithium augmentation in antidepressant-resistant patients: a quantitative analysis. Br J Psychiatry 1991;159:510-4.
6. de Montigny C. Lithium addition in treatment-resistant depression. Int Clin Psychopharmacol 1994;9[suppl 2]:31-5.
7. Delgado PL, Price LH, Charney DS, Heninger GR. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988;15:55-60.
8. Ontiveros A, Fontaine R, Elie R. Refractory depression: the addition of lithium to fluoxetine or desipramine. Acta Psychiatr Scand 1991;83:188-92.
9. Kuroda Y, Watanabe Y, McEwen BS. Tianeptine decreases both serotonin transporter mRNA and binding sites in rat brain. Eur J Pharmacol (Molecular Pharmacology Section) 1994;268:R3-R5.
10. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994; 151:1372-4.
11. Katona CLE, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DRL, Lock T, Burns RA, Robertson MM. Placebo-controlled trial of lithium augmentation of fluoxetine and Iofepramine. Br J Psychiatry 1995;166:80-6.
12. Hawley CJ, Roberts AG, Walker MH. Tolerability of combined treatment with lithium and paroxetine: 19 cases treated under open conditions. J Psychopharmacol 1994;8:266-7.
13. Dinan TG. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. Acta Psychiatr Scand 1993;88:300-1.
14. Cowen PJ, McCance SL, Ware CJ, Cohen PR, Chalmers JS, Julier DL. Lithium in tricyclic-resistant depression-correlation of increased brain 5-HT function with clinical outcome. Br J Psychiatry 1991;159:341-6.
15. McCance-Katz E, Price LH, Charney DS, Heninger GR. Serotonergic function during lithium augmentation of refractory depression. Psychopharmacology 1992; 108:93-7.
16. Nixon MK, Hascoet M, Bourin M, Colombel MC. Additive effects of lithium and antidepressants in the forced swimming test: further evidence of involvement of the serotoninergic system. Psychopharmacology 1994;115:59-64.
17. Hyttel J. Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:277-95.
18. Milne RJ, Goa KL. Citalopram - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:450-77.
19. Luo H, Richardson JS. A pharmacological comparison of citalopram, a bicyclic serotonin selective uptake inhibitor, with traditional tricyclic antidepressants. Int Clin Psychopharmacol 1993; 8:3-12.
20. Uehlinger C, Nil R, Amey M, Baumann P, Dufour H. Citalopramlithium combination treatment of elderly depressed patients: a pilot study. Int J Geriatr Psychiatry 1995; 10:281-7.
21. Øyehaug E, Ostensen ET, Salvesen B. High-performance liquid Chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr Biomed Appl 1984;308:199-208.
22. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993; 15:11-7.
23. Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther 1993;57:129-60.
24. Baumann P. Pharmakogenetik. In: Riederer P, Laux G, Pöldinger W, eds. Neuro-Psychopharmaka, vol. 1. Wien: Springer-Verlag, 1992:311-21.
25. Spina E, Caputi AP. Pharmacogenetic aspects in the metabolism of psychotropic drugs: pharmacokinetic and clinical implications. Pharmacol Res 1994;29:121-37.
26. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;48:173-82.
27. Souche A, Montaldi S, Uehlinger C, Kasas A, Reymond MJ, Reymond P, Baumann P, Dufour H. Traitement de la dépression résistante par l'association citalopram-lithium - méthodologie d'une étude multicentrique en double aveugle et résultats préliminaires. Encéphale 1991;XVII:213-9.
28. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
29. Noveske FG, Hahn KR, Flynn RJ. Possible toxicity of combined fluoxetine and lithium. Am J Psychiatry 1989;146:1515.
30. Schöpf J, Baumann P, Lemarchand T, Rey M. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. Pharmacopsychiatry 1989;22:183-7.
31. Guy W. ACDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Department of Health, Education and Welfare, 1976.
32. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Eigen K. The UKU side effect rating scale. Acta Psychiatr Scand 1987;334: 81-94.
33. Reymond P, Amey M, Souche A, Lambert S, Konrat H, Eap CB, Baumann P. Determination of plasma levels of citalopram and its demethylated and deaminated metabolites by gas chromatography and gas chromatography-mass spectrometry. J Chromatogr Biomed Appl 1993;616:221-8.
34. Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M, Koeb L, Monney C, Woggon B. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 1992; 14:1-8.
35. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ. Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991;31:350-2.
36. Montgomery SA, Pedersen V, Tanghoj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram - a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 1994;9[suppl 1]:35-10.
37. Pope HG Jr, McElroy SL, Nixon RA. Possible synergism between fluoxetine and lithium in refractory depression. Am J Psychiatry 1988;145:1292-4.
38. Öhman R, Spigset O. Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry 1993;26:263-4.
39. Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry 1989;146:278.
40. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148:705-13.
41. Brady KT, Lydiard RB, Malcolm R, Ballenger JC. Cocaine-induced psychosis. J Clin Psychiatry 1991;52:509-12.
42. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995;6:287-95.
43. Gram LF, Hansen MGJ, Sindrup SH, Brøsen K, Poulsen JH, Aaes-Jørgensen T, Overo KF. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993;15:18-24.
44. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig 1993;71:1002-9.
45. Coutts RT, Su P, Baker GB. Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J Pharmacol Toxicol Methods 1994;31:177-86.